Combination of Fruquintinib and Anti–PD-1 for the Treatment of Colorectal Cancer
Author:
Publisher
The American Association of Immunologists
Subject
Immunology,Immunology and Allergy
Reference38 articles.
1. Colorectal cancer
2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.;Stintzing;Lancet Oncol.,2016
3. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
4. PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.;Hirsch;Br. J. Cancer,2019
5. Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade.;Jacquelot;Cell Res.,2019
Cited by 49 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects;European Journal of Medicinal Chemistry;2024-10
2. Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy;Frontiers in Oncology;2024-08-20
3. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09
4. The role of innate immune cells in the colorectal cancer tumor microenvironment and advances in anti-tumor therapy research;Frontiers in Immunology;2024-07-19
5. Safety and efficacy of fruquintinib‐based therapy in patients with advanced or metastatic sarcoma;Cancer Medicine;2024-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3